Original Article
Comparison of Injectable
Ciprofloxacin and Injectable
Ceftriaxone for the Treatment of
Hospitalized Patients with Enteric
Fever
ABSTRACT
Choudhary Tariq
Masood*Maqbool Hussain**
Muhammad
AmjadChoudhary***
SaleemAbbasi****
*District Headquarter Hospital
(DHQ), Mir Pur, Azad Kashmir
** Assistant Professor, Pediatric
Medicine, Children Hospital,
PIMS, Islamabad
*** Professor of Pediatric
Surgery, Children Hospital,
PIMS, Islamabad
**** Data Manager, ARI
Research Cell/MNCHRN,
Children Hospital, PIMS,
Islamabad
182
Comparison of Injectable Ciprofloxacin and Injectable Ceftriaxone for the Treatment of Choudhary Tariq Masood et al.
183
Comparison of Injectable Ciprofloxacin and Injectable Ceftriaxone for the Treatment of Choudhary Tariq Masood et al.
Results
In this study a total of 200 cases of enteric fever
were randomly equally assigned to injection
fluoroquinolone (n=100) and injection ceftriaxone
(n=100). The average age of patients in group I
(inj. Fluoroquinolone) was 34.5 + 17.0 and in group
II (inj. Ceftriaxone) 30.6 + 14.7 years.
Approximates more than 50% of cases in both
groups were between 12 and 30 years whereas
few cases were above 61 years in group I and
group II (8% and 4% respectively). Simultaneously,
male gender was in dominance in both groups
(66% and 73%). While most of the study cases in
both groups were residing in urban area (76% and
81% respectively). (Table I)
TableI:Demographiccharacteristicsofpatientsinthe
twostudygroups
Inj.
Inj.
Fluoroquinolone Ceftrixone pvalue
GroupI(n=100)
GroupII
(n=100)
Age(years)
Upto20
31
29
21to30
20
35
31to40
20
18
41to50
11
51to60
11
61to70
71or
above
Mean+SD
34.5+17.0
30.6+14.7
Gender
Male
66(66.0%)
73(73.0%)
Female
34(34.0%)
27(27.0%)
Residence
Urban
76(76.0%)
81(81.0%)
Rural
24(24.0%)
19(19.0%)
0.17
0.08
TableII:Clinicalsignsandsymptomsofpatients
inthetwostudygroups
Headache
Anorexia
Vomiting
Coated tongue
Abdominal
pain
Fever
Constipation
Diarrhea
Toxicity
Splenomegally
Inj.
Inj.
Fluoroquinolo Ceftriaxone
ne
Group II
Group I
(n=100)
(n=100)
89 (89.0%)
90 (90.0%)
84 (84.0%)
84 (84.0%)
62 (62.0%)
67 (67.0%)
57 (57.0%)
54 (54.0%)
50 (50.0%)
55 (55.0%)
pvalue
0.81
1.0
0.55
0.77
0.57
40 (40.0%)
31 (31.0%)
20 (20.0%)
17 (17.0%)
3 (3.0%)
39 (39.0%)
32 (32.0%)
10 (10.0%)
22 (22.0%)
4 (4.0%)
1.0
0.87
0.07
0.47
1.0
Hepatomegally
1 (1.0%)
0 (0.0%)
1.0
Intestinal
perforation
Sensorium
Jaundice
Ilius
Seizures
Duration of
fever
< 1 week
> 1 week
1 (1.0%)
0 (0.0%)
1.0
1 (1.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
5 (5.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0.21
1.0
1.0
1.0
40 (40.0%)
60 (60.0%)
38 (38.0%)
62 (62.0%)
0.88
0.70
0.29
184
Comparison of Injectable Ciprofloxacin and Injectable Ceftriaxone for the Treatment of Choudhary Tariq Masood et al.
21 (21.0%)
63 (63.0%)
0.36
0 (0.0%)
1.0
4 (4.0%)
1.0
12 (12.0%)
0.12
Discussion
Ann. Pak. Inst. Med. Sci. 2014; 10(4): 182-186
185
Comparison of Injectable Ciprofloxacin and Injectable Ceftriaxone for the Treatment of Choudhary Tariq Masood et al.
Conclusion
Based on our study findings, it is concluded that
there is a great possibility that inj. ceftriaxone could
be used as first line treatment choice for enteric
fever. However, before adaptation large, well
designed and sound methodological based trials
are needed to compare first line antibiotics in the
community. The treatment of enteric fever is a
clinical challenge as well as a public health issue
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
186